Lung denervation radiofrequency ablation system completes first clinical trial

Team of doctors posing around a COPD treatment machine

A new system aimed at treating COPD with targeted lung denervation (TLD) ablation through bronchoscopy has completed its first case of registered clinical trials and will now move on to a larger study.

Broncus Holding Corporation, based in Hangzhou, China, said the randomized, controlled trial was led by Prof. Luo Fengming at the West China Hospital of Sichuan University. The Broncus study will be conducted in 26 medical centers in China and will cover the safety and effectiveness of the TLD treatment for COPD.

TLD is a bronchoscopic radiofrequncy ablation therapy for COPD that realizes denervation through targeted deep-lung tissue radiofrequency ablation in the areas rich in bronchial vagus nerves. This, in turn, reduces the airway obstruction of the whole lung and helps treat COPD.

The procedure was officially included in the 2023 Global Initiative for Chronic Obstructive Lung Disease (GOLD).

 

 

More in COPD
Page 1 of 13
Next Page